Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Survodutide
BI 456906, Boehringer Ingelheim dual agonist
A dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim for obesity and metabolic liver disease (MASH/NASH). Unlike tirzepatide (GIP/GLP-1), survodutide activates the glucagon receptor alongside GLP-1, which increases energy expenditure and hepatic fat oxidation. Phase 2 trials showed up to 18.7% weight loss at 46 weeks and significant liver fat reduction, making it a leading candidate for MASH treatment.
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
Dual agonism of glucagon and GLP-1 receptors. GLP-1 activation reduces appetite and slows gastric emptying. Glucagon activation increases hepatic fat oxidation, energy expenditure, and thermogenesis. The combination targets both caloric intake and energy output, with particular benefit for liver fat reduction — a mechanism not shared by pure GLP-1 agonists.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
- Weight management (investigational)
- MASH/NASH treatment (investigational)
- Metabolic syndrome
- Liver fat reduction
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- GI side effects (nausea, vomiting, diarrhea) — common in GLP-1 class
- Potential blood sugar effects from glucagon activation
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
Currently in Phase 3 trials for obesity (SYNCHRONIZE program) and MASH (LIVERAGE program). Phase 2 data showed 18.7% weight loss at 46 weeks and 87% relative reduction in liver fat. Potential FDA submission expected 2027. Represents a differentiated mechanism from tirzepatide and semaglutide.
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
- Survodutide for MASH: Phase 2 results (LIVERAGE)
2024 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.